The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18–60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell and N...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kuan, Jew Win, Chang, Kian Meng, Lau, Ngee Siang, Visalachy, Purushothaman, Tan, Sen Mui, Ong, Tee Chuan, Su, Anselm Ting
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2011
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3155715/
https://ncbi.nlm.nih.gov/pubmed/22942563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-011-0077-z
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki